Table 4. Cycle 3: Univariate analysis of severe neutropenia.
| Variable | Severe neutropenia (34%) | p-value | |
| No (n = 33) | Yes (n = 17) | ||
| M dose, mg/kg (mean ± SD) | 0.34±0.11 | 0.50±0.08 | |
| Median (range) | 0.33 (0.13–0.70) | 0.50 (0.33–0.69) | |
| ≤0.40 | 27 (82%) | 1 (6%) | <0.001b |
| >0.40 | 6 (18%) | 16 (94%) | |
| Chemotherapy agents | 0.15 | ||
| M only | 13 (39%) | 4 (24%) | |
| M+ T/C | 17 (52%) | 8 (47%) | |
| M+ T + C | 3 (9%) | 5 (29%) | |
| Prior treatmenta | 0.83 | ||
| No | 16 (50%) | 7 (47%) | |
| Yes | 16 (50%) | 8 (53%) | |
| Cycle 1 or 2, grade 3 or 4 neutropenia | 0.02 | ||
| No | 14 (42%) | 3 (18%) | |
| No record | 11 (33%) | 3 (18%) | |
| Yes | 8 (24%) | 11 (65%) | |
M: melphalan; T: topotecan; C: carboplatin.
a
Data not available for 3 patients (1 had and 2 did not have severe neutropenia).
b
Cut-off point selection adjusted p-value.